Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf019 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Yasuo Imanishi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan. Hauptthemen laut MEDLINE: Risedronic Acid, Aromatase Inhibitors, Breast Neoplasms, Vitamin D. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Chugai Pharmaceutical Co., Limited.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Context
Aromatase inhibitors (AIs) cause bone loss and increase fracture risk in women with hormone receptor-positive early-stage breast cancer (HR + EBC). Bone antiresorptive agents are recommended for patients at risk of fragility fractures. Eldecalcitol, combined with bisphosphonate, increases bone mineral density (BMD) in primary osteoporosis.
Objective
To determine the effect of eldecalcitol (0.75 ug/day) add-on therapy to risedronate (17.5 mg/week) on bone quantity and quality in women treated with AI.
Design
Open-label randomized control trial.
Setting
Postmenopausal women with HR + EBC (TNM stage 0-3A) treated with risedronate for more than 12 months. Patients Two hundred patients were enrolled; 196 patients were eligible for the full analysis set after excluding those without follow-up BMD data. Participants were advised to take vitamin D and calcium, yet many were vitamin D deficient or insufficient.
Intervention
Participants were randomly assigned in a 1:1 ratio to receive either eldecalcitol add-on therapy or risedronate monotherapy. Main Outcome Measure The primary outcome was the group difference in the change of lumbar spine (LS)-BMD in 24 months. Secondary outcomes included femoral neck (FN)-BMD, total hip (TH)-BMD, trabecular bone score (TBS), and the incidence of vertebral and nonvertebral fractures.
Results
The increase at LS-, FN-, and TH-BMD at 24 months was larger in the add-on therapy group than in the monotherapy group, with a group difference (add-on therapy minus monotherapy) estimate of 0.020 g/cm2 [95% confidence interval (CI): 0.010-0.029 g/cm2, P < .001] for LS-BMD. The incidence rate ratio (add-on therapy/monotherapy) for morphometric vertebral fractures was 0.292 (95% CI: 0.080-1.061, P = .061). No group difference was detected in the change in TBS.
Conclusion
Eldecalcitol add-on therapy increased LS-BMD in osteopenic to osteoporotic postmenopausal women treated with an AI and risedronate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
- Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
- Department of Health and Medical Innovation, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
- Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
- Department of Breast Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
ORCID-Profile: Yasuo Imanishi, Tetsuo Shoji
Förderung
- Chugai Pharmaceutical Co., Limited
Zitieren
APA
Imanishi, Y., Imai, T., Fujii, H., Aida, R., Nagata, Y., Shoji, T., Kashiwagi, S., Takashima, T., & Emoto, M. (2025). Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf019
Vancouver
Imanishi Y, Imai T, Fujii H, Aida R, Nagata Y, Shoji T, et al. Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf019
BibTeX
@article{Imanishi2025,
author = {Imanishi, Yasuo and Imai, Takumi and Fujii, Hisako and Aida, Rei and Nagata, Yuki and Shoji, Tetsuo and Kashiwagi, Shinichiro and Takashima, Tsutomu and Emoto, Masanori},
title = {Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf019}
}
EUVIMED